Jeremy Keller, DO
Internal Medicine · Morehead, KYNPI 1144667809
Payments from drug & device makers
Across 111 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$456
- GSK$258
- Lilly USA, LLC$184
- Novo Nordisk$135
- Boehringer Ingelheim$103
- Bayer$84
- plus $689 from 25 others
What the payments were for
- Food & beverage$1,907100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $456 |
| GSK | 15 | $258 |
| Lilly USA, LLC | 14 | $184 |
| Novo Nordisk | 8 | $135 |
| Boehringer Ingelheim | 7 | $103 |
| Bayer | 5 | $84 |
| Axsome Therapeutics, Inc. | 2 | $60 |
| Pfizer | 4 | $57 |
| Sumitomo Pharma America, Inc. | 3 | $52 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| AbbVie | 1 | $33 |
| Sanofi Pasteur Inc. | 2 | $29 |
| Exact Sciences | 2 | $28 |
| Merck | 2 | $26 |
| Tris Pharma Inc | 1 | $25 |
| Lundbeck LLC | 1 | $24 |
| Neurocrine Biosciences, Inc. | 2 | $23 |
| Seqirus USA Inc | 1 | $23 |
| Coloplast | 1 | $23 |
| Alkermes, Inc. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Tonix Medicines, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Corium, LLC | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
How this compares
$1,907 in reported general payments places this provider in the 75th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 22 | $43,688 |
| EliquisApixaban | 25 | $29,532 |
| JardianceEmpagliflozin | 24 | $27,000 |
| JanuviaSitagliptin Phosphate | 28 | $24,902 |
| Spiriva HandihalerTiotropium Bromide | 11 | $7,772 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,680 |
| Arnuity ElliptaFluticasone Furoate | 16 | $4,346 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $3,321 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $1,728 |
| Atorvastatin Calcium | 191 | $1,198 |
| Gabapentin | 120 | $860 |
| SynthroidLevothyroxine Sodium | 11 | $807 |
| Levothyroxine Sodium | 69 | $787 |
| Lisinopril | 167 | $743 |
| Ventolin HfaAlbuterol Sulfate | 11 | $728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $135 | $43,68822 claims |
| PfizerEliquis | $57 | $29,53225 claims |
| Boehringer IngelheimJardiance | $103 | $27,00024 claims |
| MerckJanuvia | $26 | $24,90228 claims |
| AstraZenecaSymbicort | $456 | $4,68014 claims |
| GSKArnuity Ellipta | $258 | $4,34616 claims |
| AbbVieSynthroid | $33 | $80711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Morehead
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
- Bernard BuchananOwensboro$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.